PE20131035A1 - Formulacion de nevirapina de liberacion prolongada - Google Patents

Formulacion de nevirapina de liberacion prolongada

Info

Publication number
PE20131035A1
PE20131035A1 PE2013000070A PE2013000070A PE20131035A1 PE 20131035 A1 PE20131035 A1 PE 20131035A1 PE 2013000070 A PE2013000070 A PE 2013000070A PE 2013000070 A PE2013000070 A PE 2013000070A PE 20131035 A1 PE20131035 A1 PE 20131035A1
Authority
PE
Peru
Prior art keywords
nevirapin
formulation
prolonged release
anhydra
nevirapine
Prior art date
Application number
PE2013000070A
Other languages
English (en)
Inventor
Michael Cappola
Svetlana Sienkiewicz
Snow Glenn Charles
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20131035A1 publication Critical patent/PE20131035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA EN COMPRIMIDOS QUE COMPRENDE: a) 400 MG DE NEVIRAPINA ANHIDRA, b) 270 MG DE HIPROMELOSA, c) 400 MG DE MONOHIDRATO DE LACTOSA Y d) 10 MG DE ESTEARATO DE MAGNESIO
PE2013000070A 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada PE20131035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
PE20131035A1 true PE20131035A1 (es) 2013-10-01

Family

ID=39739795

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000070A PE20131035A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada
PE2008000969A PE20090371A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000969A PE20090371A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Country Status (28)

Country Link
US (1) US8460704B2 (es)
EP (1) EP2155169B1 (es)
JP (1) JP5417662B2 (es)
KR (1) KR101017862B1 (es)
CN (1) CN101784263B (es)
AR (1) AR066924A1 (es)
AU (1) AU2008262031B2 (es)
BR (1) BRPI0811732A2 (es)
CA (1) CA2687491C (es)
CL (1) CL2008001678A1 (es)
CO (1) CO6150128A2 (es)
DK (1) DK2155169T3 (es)
EA (1) EA018377B1 (es)
EC (1) ECSP099561A (es)
ES (1) ES2574836T3 (es)
HU (1) HUE028598T2 (es)
IL (1) IL199924A0 (es)
MA (1) MA31430B1 (es)
MX (1) MX2009007764A (es)
NZ (1) NZ578664A (es)
PE (2) PE20131035A1 (es)
PL (1) PL2155169T3 (es)
TN (1) TN2009000510A1 (es)
TW (1) TWI419716B (es)
UA (1) UA97971C2 (es)
UY (1) UY31128A1 (es)
WO (1) WO2008154234A2 (es)
ZA (1) ZA200904939B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
EP2714045A1 (en) 2011-05-30 2014-04-09 Cipla Limited Pharmaceutical antiretroviral composition
CN104023784B (zh) * 2011-08-24 2018-05-25 费斯生物制药公司 供持续释放的活性剂制剂
IN2014MN01907A (es) * 2012-03-05 2015-07-10 Cipla Ltd
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
PT1035834E (pt) 1997-12-05 2002-09-30 Alza Corp Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
AU765909C (en) * 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
PL198797B1 (pl) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
DE60025837T2 (de) * 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
KR100738276B1 (ko) 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
EP1643946A2 (en) 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
US20070231385A1 (en) 2003-10-01 2007-10-04 Lupin Limited Controlled Release Pharmaceutical Composition and a Process for Preparing the Same
PL1696822T3 (pl) 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
US20090099154A1 (en) 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2625776A1 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release

Also Published As

Publication number Publication date
DK2155169T3 (en) 2016-06-13
AU2008262031A1 (en) 2008-12-18
JP5417662B2 (ja) 2014-02-19
IL199924A0 (en) 2010-04-15
MA31430B1 (fr) 2010-06-01
ZA200904939B (en) 2010-04-28
WO2008154234A9 (en) 2009-11-26
WO2008154234A3 (en) 2010-01-21
ES2574836T3 (es) 2016-06-22
US8460704B2 (en) 2013-06-11
CN101784263A (zh) 2010-07-21
US20100278918A1 (en) 2010-11-04
CA2687491A1 (en) 2008-12-18
TN2009000510A1 (en) 2011-03-31
UY31128A1 (es) 2009-01-30
KR20100020447A (ko) 2010-02-22
KR101017862B1 (ko) 2011-03-04
CO6150128A2 (es) 2010-04-20
WO2008154234A2 (en) 2008-12-18
EP2155169B1 (en) 2016-03-23
EP2155169A2 (en) 2010-02-24
ECSP099561A (es) 2009-09-29
CA2687491C (en) 2011-09-20
CL2008001678A1 (es) 2009-09-11
HUE028598T2 (en) 2016-12-28
NZ578664A (en) 2011-11-25
JP2010520891A (ja) 2010-06-17
AU2008262031B2 (en) 2011-08-25
MX2009007764A (es) 2009-09-10
TW200916127A (en) 2009-04-16
UA97971C2 (ru) 2012-04-10
PE20090371A1 (es) 2009-04-24
CN101784263B (zh) 2012-11-07
HK1145806A1 (en) 2011-05-06
EA200900958A1 (ru) 2010-04-30
TWI419716B (zh) 2013-12-21
PL2155169T3 (pl) 2016-09-30
EA018377B1 (ru) 2013-07-30
BRPI0811732A2 (pt) 2014-11-18
AR066924A1 (es) 2009-09-23

Similar Documents

Publication Publication Date Title
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
CR20140340A (es) Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
MA29115B1 (fr) Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
AR065096A1 (es) Preparacion solida
PE20241581A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
MX343358B (es) Tabletas de acetato de ulipristal.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
MX2012003551A (es) Tabletas transformables via oral.
UA116334C2 (uk) Тверді форми дозування бендамустину
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
IL195931A (en) Oral Pharmaceutical Preparation with Controlled Release of Active Ingredient and Methods of Manufacturing
CL2008001678A1 (es) Forma de dosificación farmacéutica de liberacion prolongada en forma de comprimido, que consiste de nevirapina anhidra, hipromelosa, lactosa monohidrato y estearato de magnesio; y su procedimiento de preparación, util para el tratamiento de una infeccion por vih-1.
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
DOP2011000406A (es) Composiciones de dosis fijas farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion en terapeutica
TN2015000135A1 (en) Modified release formulations for oprozomib
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BRPI0615989B8 (pt) formulação farmacêutica de dosagem oral
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
TR201001903A2 (tr) Uzatılmış salımlı tiyokolşiklozit tablet.

Legal Events

Date Code Title Description
FD Application declared void or lapsed